We investigated the prevalence of human papillomavirus (HPV) infection and the distribution of high-risk HPV genotypes among 2,308 high-risk Korean women to predict how much the current prophylactic HPV vaccines might affect the prevention of cervical cancer in Korea. HPV DNA was detected in 939 women (40.7%) but only one-third of women were positive for HPV-16 and/or HPV-18, the genotypes used for developing the HPV vaccines. Thus, the development of area-specific HPV vaccines based on dominant HPV genotypes in our country is needed for preventing HPV infection and the development of premalignant lesions in the cervix of Korean women.
FindingsInfection with certain types of human papillomavirus (HPV) is recognized as a causal and necessary factor for developing cervical cancer [1,2], which is the fourth of the most common cancer in South Korean women [3]. More than 140 different HPV genotypes have been characterized and approximately 50 of these genotypes are known to infect the genital tract and be oncogenic or high-risk (HR) types . HR genotypes are significantly associated with progression to invasive cervical cancer [2,4]. Therefore, assessment of the HPV genotypic spectrum among sexually active women is important for predicting public health problems such as the risks of developing cervical intraepithelial neoplasia and cervical cancer [5,6].HPV-16, the most common HR type, is detected in 50 -60% of high-grade squamous intraepithelial lesions and invasive cervical cancers and HPV-18 is followed by an incidence of 10 -20% [4,7]. Thus, HPV-16 and -18 are considered as the types responsible for causing most cervical cancers in many countries [4,7]. Clinical trials have reported that these vaccines can protect many uninfected women from developing precancerous cervical lesions caused by 9]. In spite of their high effectiveness to reduce the incidence of cervical cancer, the usefulness of these vaccines is still being debated because of the differences in the geographical distribution of HPV genotypes [10].Vaccines against HPV-16 and -18 have been developed to help the prevention of cervical cancer and the use of Merck's Gardasil (the quadrivalent vaccine for ) and GSK's Cervarix (the bivalent vaccine for HPV-16 and -18) have been licensed by the Korea Food and Drug Administration. Populationbased study for the distribution of HPV genotype is needed to predict how much these vaccines might influence to the prevention of cervical cancer.In the present study, the prevalence and distribution of HPV genotypes among high-risk women, which are called as commercial sex workers (CSWs) by other countries, were examined to predict whether the developed HPV vaccines are sufficient for preventing HPV infection and the development of premalignant lesions of the cervix in South Korea. A cohort of 2,308 high-risk women visiting for regular sexually transmitted infection testing in public health centers in four different regions (Seoul, Busan, Gwangju and Jeollanamdo) was enrolled in this study. Specimens were collecte...